A regulatory filing by Fujian Cosunter Pharmaceutical Co.,Ltd. (stock code: 300436) has come under scrutiny after multiple basic typographical errors were discovered in its 2025 private placement listing announcement, raising fresh concerns about the rigor of information disclosure review processes among listed companies.
The company formally released the announcement on September 1, 2026, detailing its targeted issuance of A-shares at a price of 82.54 yuan per share, with a total of 8.7594 million new shares that began trading on the Shenzhen Stock Exchange on September 3. However, careful inspection of this officially disclosed compliance document reveals several conspicuous textual flaws, including a duplicated phrase where "金融金融衍生产品" appears with the redundant character "金融" repeated, as well as a misspelling of the standard term "证券" as "证劵," which is a fundamental usage error in capital market terminology.
As statutory disclosure documents addressed to the capital market, investors, and regulatory bodies, private placement listing announcements carry significant weight of formality, standardization, and authority, requiring multiple layers of review and proofreading before release. While the errors found in this announcement do not affect core information such as financial data, issuance rules, or shareholding changes, and thus do not constitute a serious violation of disclosure regulations, they directly expose weaknesses in the company's information verification procedures, quality control oversight, and compliance risk management, reflecting broader deficiencies in internal controls.
Compounding the issue, according to executive compensation details in the same announcement, the company's board secretary, Zhang Qinghe, received total remuneration of 594,500 yuan for fiscal year 2025. As the primary person accountable for information disclosure, the board secretary oversees compliance management of corporate disclosures, investor relations maintenance, and monitoring of internal control processes. The appearance of such basic errors in this announcement has also triggered questions about the rigor of performance in these key duties.
Capital markets demand high precision and standardization in listed company disclosures, and while typographical mistakes may seem trivial, they directly influence corporate market image and investor confidence. Industry insiders suggest that listed companies must strengthen their full-cycle disclosure review mechanisms, firmly establish accountability at each position, and refine every step of proofreading, verification, and final review to eliminate avoidable textual errors, thereby safeguarding the authenticity, accuracy, completeness, and conformity of information disclosure, and upholding the integrity of capital market disclosure standards. As of now, Cosunter has yet to issue any corrective statement or explanation regarding the textual errors found in the announcement.